<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04668859</url>
  </required_header>
  <id_info>
    <org_study_id>2016-097</org_study_id>
    <nct_id>NCT04668859</nct_id>
  </id_info>
  <brief_title>Midodrine as Novel Treatment of Post-Cardiopulmonary Bypass Vasoplegic Syndrome</brief_title>
  <official_title>Midodrine as Novel Treatment of Post-Cardiopulmonary Bypass Vasoplegic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vasoplegic syndrome (VS) is a common and serious complication of cardiopulmonary bypass (CPB)&#xD;
      procedures associated with a significant increase in morbidity and mortality [1-5]. VS is&#xD;
      defined as significant hypotension, high or normal cardiac outputs, low systemic vascular&#xD;
      resistance, low cardiac filling pressures, and vasopressor requirement despite adequate fluid&#xD;
      resuscitation following CPB [1-2]. Extensive research has been performed regarding the&#xD;
      pathophysiologic response to CPB and risk factors associated with VS. No safe and effective&#xD;
      preventive strategy has gained widespread use. Supportive care with intravenous (IV)&#xD;
      vasopressors has thus been adopted as standard of care [6]. The use of these medications,&#xD;
      while effective in the majority of patients, generally necessitates close monitoring in an&#xD;
      intensive care unit (ICU) setting. These patients are subject to prolonged ICU and hospital&#xD;
      stays, as well as the potential complications of prolonged use of central venous lines (CVL)&#xD;
      required to give these medications [1-3,7]. Recent studies suggest midodrine, a generic oral&#xD;
      vasopressor, may accelerate the decline in IV vasopressor requirements in select ICU patients&#xD;
      [8-10]. At our institution, the addition of midodrine to IV vasopressors for the treatment of&#xD;
      VS has been observed to be effective in reducing IV vasopressor duration. No literature&#xD;
      exists describing the use of midodrine in this patient population. The goal of this study is&#xD;
      to investigate the novel use of midodrine in CPB surgery complicated by VS. Ultimately, we&#xD;
      hope to produce literature supporting its use that may be applied on a global scale to&#xD;
      improve patient care&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI relocated&#xD;
  </why_stopped>
  <start_date type="Actual">July 29, 2016</start_date>
  <completion_date type="Actual">August 8, 2018</completion_date>
  <primary_completion_date type="Actual">August 8, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from procedure end until discontinuation of IV vasopressors</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of decline in IV vasopressor dose</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time until CVL removal</measure>
    <time_frame>12 mothns</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major infections/complications</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>in-hospital and 30-day mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Use of Midodrine in Post-cardiopulmonary Bypass Vasoplegic Syndrome</condition>
  <arm_group>
    <arm_group_label>Midodrine Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive the drug Midodrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine</intervention_name>
    <description>oral vasoactive that is metabolized by the liver an peripheral tissues into desglymidodrine, an active metabolite. It produces arteriolar and venous constriction with a subsequent elevation in blood pressure.</description>
    <arm_group_label>Midodrine Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylcellulose</intervention_name>
    <description>Placebo will consist of inert methylcellulose</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  post-cardiopulmonary bypass surgery&#xD;
&#xD;
          -  vasoplegic syndrome criteria&#xD;
&#xD;
               1. MAP &lt; 65mmHg&#xD;
&#xD;
               2. Cardiac index&gt;/=2.4 L/min/m^2, as determined by Swan-&#xD;
&#xD;
               3. systemic vascular resistance index &lt;/=1400 dynes s/cm^5/m^2&#xD;
&#xD;
               4. adequate fluid resuscitation as determined by treating critical care team&#xD;
&#xD;
          -  vasopressor requirement&#xD;
&#xD;
               1. norepinephrine 0.05-0.5 mcg/kg/min WITH/WITHOUT&#xD;
&#xD;
               2. vasopressin any dose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergy to midodrine&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  midodrine or cardiac glycoside as preadmission medication&#xD;
&#xD;
          -  history of orthostatic hypotension, thyrotoxicosis, or pheochromocytoma&#xD;
&#xD;
          -  severe organic heart disease (endocarditis, untreated congenital or rheumatic heart&#xD;
             disease)&#xD;
&#xD;
          -  liver failure/cirrhosis&#xD;
&#xD;
          -  chronic kidney disease (GFR &lt;30mL/hr)&#xD;
&#xD;
          -  ventricular assist device implantation procedure, intra-aortic balloon pump placement,&#xD;
             or heart transplantion&#xD;
&#xD;
          -  unresolved post-operative acute kidney injury (rise in serum creatinine by &gt;/=&#xD;
             0.5mg/dl from baseline&#xD;
&#xD;
          -  inadequate tissue oxygenation (lactate &gt; 2 mmol/L)&#xD;
&#xD;
          -  inability to take oral medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasoplegia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midodrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

